新序贯疗法治疗难治性幽门螺杆菌感染的临床研究  

Clinical Study on New Sequential Therapy in the Treatment of Refractory Helicobacter Pylori Infection

作　　者：郑仁斌[1] 黄夺夏[1] 

机构地区：[1]福建医科大学附属宁德市闽东医院,福建省宁德市355000

出　　处：《临床合理用药杂志》2014年第30期10-11,共2页Chinese Journal of Clinical Rational Drug Use

摘　　要：目的探讨新序贯疗法治疗难治性幽门螺杆菌(Hp)感染的治疗疗效。方法选取2011年6月—2013年6月我科收治的经一次标准三联疗法(质子泵抑制剂或铋剂+2种抗生素治疗7d)治疗失败的患者80例,随机分成治疗组和对照组,治疗组40例采用10d新序贯疗法,对照组40例采用10d传统四联疗法。比较两组Hp根除率。结果治疗组Hp根除率为85.0%(34/40),对照组Hp根除率为65.0%(26/40),差异有统计学意义(P<0.05)。两组均未出现严重不良反应。结论新序贯疗法治疗难治性Hp感染的疗效确切。Objective To study the effect of new sequential therapy in the treatment of refractory Helicobacter pylori（ Hp） infection. Methods A total of 80 failure cases treated by standard triple therapy of eradicating Hp in our hospital from June 2011 to June 2013 were selected,then they were randomly divided into treatment group and control group,40 cases in each. Patients in treatment group were treated with 10 days new sequential therapy,while patients in control group were treated with the 10 days traditional quadruple therapy. The Hp eradication rate between the two groups were compared. Results The Hp eradication rate of treatment group was 85. 0%（ 34 /40）,that of the control group was 65. 0%（ 26 /40）,the difference was statistically significant（ P〈0. 05）. No one of the two groups occurred severe adverse reactions. Conclusion New sequential therapy has remarkable effect in the treatment of refractory Hp infection.

关 键 词：螺杆菌 幽门 感染 序贯疗法 

分 类 号：R573.6[医药卫生—消化系统]